To Our Shareholders
and Investors

• April 18, 2025

  R & D
  FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
• March 28, 2025

  R & D
  Submission of New Drug Application for NS-401 (Tagraxofusp) in Japan
• March 19, 2025

  Pharmaceuticals
  Launch of Uptravi® Tablets for Pediatric 0.05 mg for the Treatment of Pulmonary Arterial Hypertension in Japan
• March 05, 2025

  R & D
  CAP-1002: The U.S. FDA has accepted the Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy

Upcoming Events

• May 08, 2025

  IR Meeting (Q4/FY2024)

• May 08, 2025

  FY2024 Annual results announcement

• February 18, 2025
  R&D Meeting PDF1.7 MB
• February 07, 2025
  Conference Call(Q3/FY2024) PDF921 KB
• February 07, 2025
  FY2024 3rd Qtr results announcement PDF780 KB